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Abstract: Inflammatory bowel disease (IBD) is a chronic disease mediated by the immune system 
and characterized by the importance of diet in pathological development. This study aims to under-
stand how the use of predefined diets can affect the adult population diagnosed with IBD. We con-
ducted a systematic review and meta-analysis. From the different databases (MEDLINE, Scopus, 
Cochrane, LILACS, CINAHL, and WOS), we found 4195 registers. After a review process, only 31 
research studies were selected for qualitative synthesis and 10 were selected for meta-analysis. The 
variables used were Crohn’s Disease Activity Index (CDAI) for patients with Crohn’s Disease (CD) 
and fecal calprotectin (FC), C-Reactive Protein (CRP), and albumin (ALB) for patients with IBD. 
Predefined diets have been shown to have partial efficacy for the treatment of IBD and are compat-
ible with other medical treatments. CDAI improved but with reasonable doubts due to the high 
heterogeneity of the data, while no differences were observed for ALB, FC, and CRP. More studies 
that evaluate the influence of predefined diets on IBD patients are needed due to the great variability 
in diets and the tools used to measure their effects. 




Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the 
gastrointestinal tract with periods of remission or recurrence and includes both Crohn’s 
disease (CD) and ulcerative colitis (UC) [1]. 
In CD, inflammation can be present in any area of the entire gastrointestinal tract, 
whereas in UC, the inflammatory process affects only the colon [2]. 
The symptoms of this type of disease are diverse, including the appearance of diar-
rhea, bloody stools, abdominal pain, fatigue, weight loss, etc. [3]. The prevalence exceeds 
0.3% in North America, Oceania, and many European countries, and the incidence of 
these types of pathologies has increased rapidly in recently industrialized countries, pro-
ducing a high burden on health systems [4,5].  
IBD, apart from being treated with expensive medical treatments to alleviate its ac-
tivity, leads to a decrease in the patient’s quality of life that can affect the degree of disa-
bility and work productivity and is associated with more symptoms of anxiety and de-
pression [6–8]. In addition, malnutrition and specific nutritional deficiencies are frequent 
among these types of patients, depending on the state and/or progress of the disease, and 
most patients impose dietary restrictions based on their own beliefs [9,10]. 
The etiology of IBD is unknown; in fact, it is a multifactorial disease. However, West-
ernised lifestyles and diets are one of the main drivers of the increasing incidence [11,12]. 
Diet plays an important role in the gut’s microbial composition and functioning, intestinal 
barrier, host immunity, and intestinal physiology [12,13]. 
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Regarding nutritional treatment, for artificial nutrition, such as enteral and paren-
teral nutrition, there is evidence of efficacy [14,15], but for natural nutrition, it seems that 
a diet that is low in fiber, high in fat, and high in carbohydrates can lead to severe dysbio-
sis, while one richer in fruits, vegetables, and olive oil could prevent it. However, together 
with the role of certain foods such as meat, fish, and dairy products, their role in the de-
velopment of the disease is controversial and uncertain in the absence of studies [16–18].  
On the other hand, while for pediatric patients it seems that the implementation of 
predefined diets, such as the specific carbohydrate diet (SCD) or the Crohn’s disease ex-
clusion diet (CDED), is positive [19], for the adult population, the studies performed to 
date have been inconclusive and the findings are inconsistent in addition to being mostly 
concerned with symptomatology of the inactive disease. [20–23]. 
Therefore, there is a need for more and clearer evidence that allows health profes-
sionals to increase their knowledge in order to advise their patients on what type of spe-
cific dietary formulas or nutrients they will need that will allow them not only to comply 
with nutritional requirements but also to improve the outcome of their symptoms, with 
positive repercussions for a better quality of life [24,25]. 
The aim of this study is to understand how predefined diets, as interventions, can 
affect the adult population diagnosed with IBD, which will improve the dietary state-
ments of current clinical guidelines [26,27]. 
2. Materials and Methods 
To achieve this objective, a systematic review was conducted in agreement with the 
procedures and verification list described by PRISMA [28]. Afterwards, a meta-analysis 
on the more common results was conducted. 
2.1. Systematic Review 
A search of scientific works was conducted in the MEDLINE database, through the 
open retrieval system on the Internet such as PubMed, the Cochrane Library, Scopus, Web 
of Science, CINAHL, and LILACS. Studies conducted up to 10 January 2020 were com-
piled. 
2.1.1. Inclusion and Exclusion Criteria 
The studies selected had to comply with the following inclusion criteria: refers to an 
adult population (older than 18) diagnosed with IBD; studies the effect of predefined diets 
within IBD; be clinical trials and observational studies; be in English, Spanish, Portuguese, 
French, or German.  
The following articles were excluded: those that referred to the infant population, to 
animals, or to the use of predefined diets in a healthy adult population and those that 
sought the effect of specific foods or nutrients in IBD, without a clear diet designation, 
that were case report studies, or that were based on secondary sources. 
2.1.2. Search Equation 
To include content linked to the intervention and predefined diets, two specific de-
scriptors were used, such as “Nutrition Therapy” and “Diet”, and the same terms were 
used in the title or abstract. 
For content linked to the population, we utilized the descriptor that referred to the 
disease, “Inflammatory bowel diseases”, and its equivalent term in the title or abstract. 
Also, the filters “Humans” and “Adult” were utilized to achieve our objective. 
Therefore, the main search equation designed for this study was as follows: 
((“Nutrition Therapy” [Mesh] OR “Nutrition Therapy” [Title/Abstract] OR “Diet” 
[Mesh] OR “Diet” [Title/Abstract]) AND (“Inflammatory Bowel Diseases” [Mesh] OR “In-
flammatory Bowel Disease” [Title/Abstract])) AND (Humans [Mesh] AND adult [MeSH]) 
The search equation was adapted to each and all of the databases described previ-
ously. The process was conducted in the period from December 2019 to January 2020. 
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2.1.3. Selection Process 
After eliminating duplicate records, the process of selection was conducted in two 
phases. The first consisted of reviewing the titles and abstracts of all the article records 
resulting from the adapted search equations and shown by the databases by using the 
inclusion and exclusion criteria and the objective of the study as the screening measures. 
The screening and selection of the records/articles were conducted independently by the 
two researchers, both experts in the fields of nutrition. These researchers agreed on the 
discrepancies found in order to define the final suitability of the records/articles found in 
the databases. The precision of the search was calculated based on the ratio of full-text 
articles selected for the review divided by the number of records found by the search 
equation and multiplied by one hundred. 
The second phase involved the application of inclusion/exclusion criteria to the com-
plete text of all the scientific studies selected in the first phase, thus ensuring the relevance 
of each one of them. In order to obtain studies that were not accessible via the Internet, we 
used three methods: Researchgate, the corresponding author, and interlibrary loan. 
2.1.4. Evaluation of the Quality of the Studies 
Evaluation of the methodological quality of the included studies was performed by 
two independent researchers, using the CONSORT (Consolidated Standards of Reporting 
Trials) guide for clinical trials and STROBE (Strengthening the Reporting of Observational 
studies in Epidemiology) for observational studies. 
These guides contain a list of 25 (CONSORT) and 22 (STROBE) essential aspects that 
should be described in the publication of these studies. For each selected study, one point 
was assigned for each item present (if not applicable, it was not scored). When an item 
was composed of several points, these were evaluated independently, giving the same 
value to each of them, and subsequently an average was made (being the final result of 
that item), so that in no case could it beat the score of one point per item [29–31]. 
2.2. Meta-Analysis 
To calculate the effect size of the enteral nutrition on the variables Crohn’s Disease 
Activity Index (CDAI), albumin (ALB), Fecal Calprotectin (FC), and C-Reactive Protein 
(CRP), a meta-analysis was performed. For this, the model of fixed effects and the model 
of random effects were used. The results are presented as a forest plot along with the 
percent heterogeneity and its confidence interval at 95%, the t-value, and the heterogene-
ity test. 
To explore the influence of each study over effect size, we used a leave-one-out 
method; pooled estimates were calculated omitting one study at a time. In addition, we 
plotted a scatterplot introduced by Baujat et al. [32]. On the x-axis, the contribution of each 
study to the overall heterogeneity statistic was plotted. On the y-axis, the standardized 
difference of the overall treatment effect with and without each study was plotted; this 
quantity describes the influence of each study on the overall treatment effect. Therefore, 
studies that fall on the top right quadrant of the Baujat plot have the most influence.  
Publication bias occurs only when favorable results are published, and this could 
have consequences on the results of the meta-analyses if these are included. To analyze 
the publication bias, a nonparametric analysis was conducted, as proposed by Duval and 
Tweedie [33] based on the funnel-plot, by estimating and adjusting for the number and 
outcomes of missing studies in the meta-analysis. Another less-conservative proposal to 
estimate the number and outcomes of missing studies is the proposal by Copas et al. [34].  
A meta-regression could not be performed due to the low number of studies. All 
calculations were performed within an R programming environment utilizing the pack-
ages meta version 4.15-1 [35,36] and metasens version 0.5–0 [37]. 
  




As a result of the specific search equations used in the different databases, a total of 
5645 records of scientific articles were found. A total of 1450 records were duplicated, 
leaving a total of 4195 records without duplication. In the first phase of the study, exactly 
4135 study records were discarded, leaving 60 full-text studies to review, so that the accu-
racy was 1%. As shown in Figure 1, 2514 records did not study the effect of predefined 
diets, 576 did not refer to humans, 499 showed that the study utilized a design that was 
not adequate, 283 did not use an adult population, 189 did not refer to IBD, 64 were still 
being conducted without showing results, and 10 were written in another language other 
than the ones cited above. 
 
Figure 1. Identification and selection of studies/records in the databases. 
In the second phase, 29 studies were removed: 20 because they did not investigate 
the effects of predefined diets, 6 due to defects in design, and 3 because the patients stud-
ied were not adults. Therefore, only 31 research studies  [38–68]were selected, as shown 
in Figure 1. 
As for the designs of the experimental studies included, 13 controlled and random-
ized clinical studies (41.9%); 3 non-randomized, controlled clinical trials (9.7%); and 3 non-
randomized, non-controlled clinical trials (9.7%) were found.  
Lastly, for the designs of the observational studies included, 6 cross-sectional studies 
(19.4%), 3 cohort studies (9.7%), 2 retrospective cohort studies (6.5%), and 1 case-control 
(3.2%) study were found. 
In addition, 14 of the studies found showed results that specifically referred to CD, 4 
studies referred to UC, and 13 studies showed results for both UC and CD under the cat-
egory of IBD. Also, 8 studies mentioned the results of the disease in its active form, 3 
studies reported disease outcomes of patients under surgery, 15 studies used a population 
with IBD in remission, and 5 studies did not indicate disease status. Figure 2 shows this 
information in a chronological manner. 
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Figure 2. Chronological review according to type of study and sample size: red points, clinical trials; blue points, obser-
vational Studies. 
As for the variety of predefined diets used in the studies, a total of 17 different types 
were found as shown in the Table 1. 
Table 1. Predefined diets in systematic review studies. 
Number of Stud-
ies 
Type of Predefined Diet 
Number of Stud-
ies 
Type of Predefined Diet 
9 
Low fermentable oligosaccharides, disaccharides, monosaccharides 
and polyols diet (LFD) 1 
Dietary modification framework for UC 
(DMF-UC) 
5 Immunoglobulin exclusion diet (IGED) 1 Specific food intolerance diet (SFID) 
4 Unrefined carbohydrate fiber rich diet (UCFR) 
1 Typical Australin diet (TAD) 
2 Microparticles diet (MD) 
2 Mediterranean diet (MED) 1 Specific carbohydrate diet (SCD) 
2 Gluten-free diet (GFD) 1 Komperod elimination diet (KED) 
2 Refined carbohydrate diet (RCD) 1 Autoimmune protocol diet (AIPD) 
1 Semi-vegetarian diet (SVD) 1 Plant-based diet (PBD) 
1 Mediterranean-inspired anti-inflammatory diet (MIAID) 1 Vegetarian diet (VD) 
The total population analyzed in the research studies found included a total of 5331 
individuals with IBD: 829 diagnosed with CD and 422 with UC. 
The main tools utilized by the researchers to obtain results were scores, biomarkers, 
and tests to measure the activity of the disease: the Crohn’s Disease Activity Index (CDAI), 
the Harvey–Bradshaw Index (HBI), the Van Hees index (VHI), the Modified Truelove and 
Witts activity index (MTWAI), the Mayo score (MS), the partial Mayo score (PMS), irrita-
ble bowel syndrome severity score system (IBS-SSS), Copenhagen IBS disease courses 
(CIBSC) visual analogue scales (VAS); biomarkers such as CRP, ESR, the white blood cell 
count (WBC), levels of albumin (ALB), pre-albumin (PA), transferrin (TRF), hemoglobin, 
platelet count (PL), alkaline phosphatase (ALP), etc.; and medical tests such as an ileoco-
lonoscopy. Complementary tests were also included, such as urine, feces samples, and 
Bristol stool (BS) tests. Tests that measured the body’s composition were also found, such 
as anthropometries and bioimpedance, to obtain parameters such as body weight (BW) 
and body mass index (BMI). Quality of life questionnaires included the IBD Questionnaire 
(IBDQ), the short IBD Questionnaire (SIBDQ), the United Kingdom version of IBDQ 
(IBDQ-UK), and the irritable bowel syndrome quality of life questionnaire (IBS-QOL). 
Table 2 schematically shows the main results found in the selected articles. Table 3 
and Table 4 show the scores obtained by the studies for their methodological quality ac-
cording to the CONSORT and STROBE guidelines.
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Table 2. Main results of the systematic review. 
Author Study n/age Disease P/m CC Treatment Variables Main Results 









52 GBR UCFR and ND Admission to hospital, 
IOP, EIMs 
The number of hospital admissions required in UCFR 
patients was 11 compared with 34 in the ND (p < 0.01). 
UCFR patients spent a total of 111 days in hospitals 
compared with 533 days for ND (p < 0.005). Intestinal 
operations were performed on only one UCFR patient 
but on five ND. 
Berghouse et 








0.5 GBR UCRF and RCD 
7-FR, chemical analysis of 
the ileostomy fluid 
Compliance with the dietary advice was good. A 
dietary assessment was possible in 7/10 patients. The 
amount of ileostomy effluent was significantly greater 
on the UCRF both in terms of wet weight (238 ± 89 g 
vs 162 ± 79 g) and dry weight (23.6 ± 6.8 g vs 14−9 ± 
6−6 g). 
Jones et al. 











CDAI, ESR, length of 
remission, orosomucoid 
At 6 months, 7 patients on an SFID remained well (p < 
0.05, Fisher´s exact test). The mean time to relapse was 
1.38 ± 1.74 (SD) months in the UCFR group and 2.75 ± 
1.98 months in the SFID group. For patients on the 
SFID who remained in remission for 6 months, the 
ESR (mean ± SD) dropped from 39.7 ± 21.7 mm/h 
before the trial to 16.2 ± 12.5 (p < 0.05) at 6 months and 
their orosomucoid concentrations dropped from 232.5 
± 68.2% before the trial to 140 ± 41.5% (p < 0.05) at 6 
months. 










24 GBR UCFR and RCD RC, clinical deterioration, 
7-FR, BW 
178 patients completed the trial. The cumulative 
proportion of patients remaining in the trial without 
deterioration of the disease was 64% in RCD and 59% 
in UCFR. The clinical score, stool count, and BW 
showed no significant changes with either diet. 










4 GBR LMD and NMD CDAI, HEMA, CA, and 
ALB 
Despite a higher CDAI at month 0 in the LMD group, 
compared to the NMD group, there was a significantly 
lower CDAI in the LMD group by month 4 (145 ± 47 
vs 295 ± 25). All patients had normal CA levels, 
corrected for ALB, and there were no significant 
changes in nutritional status in either group. 
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CDAI, VHI, IBDQ, ESR, 
CRP, FC, IP 
No differences were found between the low and 
normal calcium groups for CDAI, VHI, IBDQ, CRP, 
ESR, FC, or IP, neither between the low and normal 
dietary calcium groups nor between the low and 
normal microparticle groups. 











1.5 AUS LFD 
FL, SF, DH, adherence to 
diet 
In the RCS, adherence was good in 5/7 patients, while 
in the CS, it was 3/8; 5/7 studied retrospectively 
improved stool frequency (from median 8 to 4 per 
day; p < 0.05). In CS, only 5 patients were evaluable for 
the effect of diet on SF, with no change seen. For the 7 
patients without pouchitis, median daily SF fell from 8 
to 4 (p < 0.001). 
Gearry et al. 







3 AUS LFD 
Adherence to diet, change 
of gastrointestinal 
symptoms 
Overall abdominal symptoms, abdominal pain, 
bloating, wind, and diarrhea improved in patients 
with CD and UC (p < 0.02 for all), but constipation did 
not. The median response for LFD implementation 
was 3/10 “easy” (SD 2.9, range 0–10, interquartile 
range 0.25–5). 
Benz et al. 








1.5 GER IGED and CG (Sham diet) 
GISD, SF. and general 
well-being 
An average reduction in the total weekly score of 6.5 
points was estimated for the IGED group compared 
with the CG (95% CI: −0.6, 13.6 points). The estimated 
effect seems to have a clinically relevant effect but is 
not significant (p = 0.07). The daily SF significantly 
decreased by 11% during an IGED compared with CG. 















CDAI, CRP, BMI, ALB, 
CHOL, CHE, HEM, 
morphological studies, 
FFQ 
Among the 16 (73%) patients who continued with the 
SVD, 15 maintained remission and one relapsed; the 
remission rate was 100% at 1 year and 92% at 2 years. 
The cumulative relapse rate at 2 years was 
significantly lower in the SVD group than in the 
omnivorous group. The concentration of CRP was 
normal at the final visit in more than half of the 
patients in remission on an SVD. 
Rajendran et 





CD 1 GBR IGED MCDAI, ESR, CRP, ALB 
The mean mCDAI score on entry to the trial was 171 ± 
108, and after IGED, the mCDAI decreased to 97.5 ± 87 
(p < 0.05). The general “well-being” rating improved 
from 0.88 to 0.63 (p < 0.05). The mean ESR fell from 
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22.3 ± 16.0 to 17.1 ± 15.2 (p = 0.032). CRP and ALB 
levels did not change significantly. 
Uzunismail et 













FC, CRP, ESR, WBC, PL, 
HBI, CDAI 
The mean CDAI score before the provocation was 63 ± 
29.9 and increased statistically significant to 99.75 ± 
46.1 (46–183) during provocation. The HBI score, 
WBC, CRP, and WBC also increased significantly. 
Marlow et al. 





CD 1.5 NZL MIAID 
CRP, DNA damage, and 
microbiota 
Subjects self-reported good adherence to diet; 
cholesterol levels were reduced by 20%. CRP and 
micronuclei numbers showed a trend of reduction 
after the 6-week diet; however, this was not 
significant. 
Herfarth et al. 









14 USA GFD GFDQ 
In the GFD group, 206 (65.6%) reported that they 
experienced an improvement of at least 1 specific 
clinical symptom, which has been associated with 
gluten exposure; 38.3% also recounted fewer and less 
severe flares while being on a GFD, and 23.6% stated 
that they required fewer medications to control the 
disease. Excellent adherence was associated with 
significant improvement of fatigue. 
Kyaw et al. 
2014 [52] RCCT 






6 GBR DMF-UC and ND IBDQ-UK, SCCAI, FFQ 
The mean difference between SCCAI at week 0 and 
week 24 was a reduction by 1.304 (p = 0.0108) in the 
DMF-UC group. For the ND group, there was an 
increase in the mean differences between SCCAI at 
week 0 and week 32 of 0.875 (p = 0.0249). There were 
no significant differences in the IBDQ score; 69% of 
patients in the DMF-UC group found the dietary 
advice significantly or moderately helpful. 
Gunasekeera 









1 GBR IGED and CG SIBDQ, CDAI, HBI, CRP, 
FC 
There was a 3.05 (0.01–6.11), p < 0.05, improvement in 
SIBDQ and 41 (10.4–71.5) in CDAI, p = 0.009. There 
was no significant difference in FC and CRP levels. 









0.75 AUS LFD, TAD and 
ND 
FM, fecal pH, FSCFA, 
VAS (symptoms), FWC, 
FC 
FC was also similar across the three phases of the 
study, but in 3 subjects, it was consistently >150 μg/g. 
Dietary adherence during the interventional diets was 
good. The severity of overall gastrointestinal 
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symptoms was significantly less on the last 14 days of 
the LFD at mean 13.5 mm compared with the last 14 
days of the TAD at 24.8 mm 








16 DEN LFD 
VAS, FARS, assess 
satisfaction with LFD, BS, 
CIBSC, IBS-SSS, IBS-QOL, 
SIBDQ 
The patients experiencing full effectiveness were 
greater in the IBD group than in the IBS group (42% vs 
29%, p = 0.08). At follow-up, the median IBS-QoL score 
was 75 (range: 37–145) for the IBS group and 63 
(range: 36–126) for the IBD group. For the IBD patients 
only, the median SIBDQ score was 55; 32% of the IBS 
group and 37% of the IBD group were on the diet for 
less than 3 months, while 47% and 50%, respectively, 
stayed on the diet until follow-up. The overall median 
IBS-SSS score at follow-up was 211 (range: 16–487). 









1.5 GBR LFD SRFGS, GRRS, BS 
There was a significant increase in the proportion with 
satisfactory relief of their FGS following a LFD. 
Individual symptom severity scores decreased 
following LFD with the greatest reductions in scores 
observed for bloating and flatulence, followed by 
abdominal pain and lethargy. More patients reported 
normal consistency and normal-frequency stools 
following the LFD (p < 0.05) 
Suskind et al. 




IBD 12 USA SCD 




extent, duration, etc) 
The reason for individuals starting the SCD was for 
avoidance of medication (49%), incomplete 
improvement with medication (28%), no improvement 
with medication (9%), and/or side effects or allergies 
to medication (19%). Overall, symptoms such as 
abdominal pain, limitations in activities, diarrhea, 
blood in the stool, and weight loss decreased over 
time; 4% reported clinical remission prior to the SCD, 
while 33% reported remission at 2 months after 
initiation of the SCD, and 42% reported both at 6 and 
12 months 
Komperod et 







0.5 NOR KED and ND GISD, VAS (symptom 
intensity), FC 
A significant decline in symptom intensity was 
consistently seen across all seven symptoms when we 
compared symptoms at week 2 of the ND to 
symptoms at week 2 of the KED. 
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2.75 USA AIPD 
Clinical remission, 
complications, HBI, PMS, 
SF, RB, PGA, CRP, FC, 
ALB, SIBDQ 
Clinical remission was achieved at week 6 by 11/15 
(73%) study participants (6 CD and 5 UC). Mean total 
SIBDQ scores significantly improved from 46.5 (SD 
12.5) at baseline to 53.3 (SD 10.9) at week 6 and 60.5 
(SD 4.8) at week 11. From week 0 to weeks 6 and 11, 
mean PMS significantly improved from 5.8 (SD 1.2) to 
1.2 (SD 2.0) and 1.0 (SD 2.0) for UC and mean HBI 
significantly improved from 7 (SD 1.5) to 3.6 (SD 2.1) 
and 3.4 (SD 2.6) for CD. CRP and FC did not 
significantly change during the study 










1.5 DEN LFD and ND 
IBS-SSS, SCCAI, HBI, FC, 
CRP, SIBDQ, IBS-QOL, 
FFQ 
At 6 weeks, a significantly lower IBS-SSS score was 
observed in the LFD group (median IBS-SSS 115, IQR 
33–169) as compared to the ND group (median IBS-
SSS 170, IQR 91–288), p = 0.02. At week 6, a statistically 
significant improvement in SIBDQ was observed in 
those on a LFD (median 60, IQR 51–65) when 
compared to those on a ND (median 50, IQR 39–60). 
No significant differences were found between the 
LFD and ND groups with regards to FC and CRP 
change. 










42 JPN PBD 
PBDS, relapses, and 
remissions 
(improvement) 
Of 57 cases, 8 (4/28 IEC and 4/29 RC) relapsed during 
the follow-up period. Cumulative relapse rates at 1, 2, 
3, 4, and 5 years were 2%, 4%, 7%, 19%, and 19%, 
respectively. Mean time to relapse was 7 years 3 
months. There were no differences between groups. 
Most patients (77%) experienced some improvement. 
The short- and long-term PBD scores after 
hospitalization were higher than baseline PBD scores. 









6 CHN IGED and ND MS, EIMs, BMI, ALB, TRF, PA, IBDQ, MF 
MS in the ND group was significantly higher than that 
in the IGED group (3.52 ± 1.15 vs 2.41 ± 0.89) and the 
endoscopic appearance tended to be better in the 
IGED group at 6 months. After dietary intervention, 
BMI and ALB were significantly higher in the IGED 
group than in the ND group (23.88 ± 3.31 vs 21.50 ± 
6.24 kg/m2, respectively, 48.05 ± 6.39 vs 45.72 ± 5.48 
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g/L). There were no significant differences in PA, TRF, 
and IBDQ between the groups.  
Testa et al. 








3 ITA LFD IBS-SSS, SF-36, 7-FR  
In the IBD population, the average IBS-SSS scores 
were 207 ± 88 SD at T0, 139 ± 50 SD at T1, and 73 ± 45 
SD at T3 (p < 0.001), demonstrating a good response to 
LFD. In most of the SF-36 domains, there was a 
significant improvement from T0 to T3 for all groups; 
8/127 (6.3%) patients revealed poor adherence. 
Bodini et al. 









1.5 ITA LFD and ND CRP, FC, PMS, HBI, IBDQ 
After 6 weeks of treatment in the LFD group, in 
patients with CD, median HBI significantly decreased. 
A statistically significant decrease was observed in 
median calprotectin values. A significant increase in 
median IBDQ was detected. However, there were no 
significant differences between groups for any 
parameter. 









36 ISR MED FFQ, MedDiet, PDAI, 
CRP, FC PGA 
Patients with an inactive disease tended to have a 
higher MED score compared to those with an active 
disease, but this difference did not achieve statistical 
significance (4.7 ± 1.8 vs. 4.3 ± 1.7). The MED score was 
associated with lower odds for elevated FC (adjusted 
OR = 0.74 [95% CI 0.56–0.99], p < 0.05). Patients who 
had highly adhered to MED (MED score ≥ 5) had 
lower rates of pouchitis than patients with low 
adherence to the MED (26% vs. 45.4%, log rank test, p 
= 0.17). 









6 GRE MED 
MedDiet, HBI, IBDQ, BW, 
BMI FE, HDL, LDL, TG, 
LDH, SGOT, SGPT, γ-GT, 
ALP, CRP, IL-6, and IL-10 
Adherence was higher in REM-CD than ACT-CD (26.8 
± 5.0 vs 30.2 ± 5.8, p = 0.005). Protein intake (p = 0.015) 
and vitamin C (p = 0.003) levels were individually 
higher in the REM-CD. In the regression models 
adjusted for age, sex, BMI, and smoking, HBI showed 
a highly significant negative linear association with 
the MedDiet score and IBDQ showed a positive linear 
association with the MedDiet score. 
Schreiner et 










SUI GFD, VD and ND DQ, clinical 
characteristics, SF-36 
The authors did not find significant differences in 
either GFD or VD patient disease activities based on 
CDAI and MTWAI. VD patients had higher scores on 
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the posttraumatic stress diagnostic scale and poorer 
mental health. A GFD was associated with lower 
scores in the physical and mental component survey 
(SF-36) and higher anxiety and depression scores. 










1 GBR LFD and ED 
IBS-SSS, GSRS, IBDQ-UK, 
SF, BS, HBI, PMS, 7-FC, 
CRP, FC, FM, FSCFA 
There were 6 adverse events during the trial. There 
were no statistically significant differences between 
groups in total IBS-SSS score, HBI, PMS, FC, and CRP. 
The severity of flatulence, bloating, and SF was 
significantly lower during LFD compared with ED. 
Total IBDQ-UK was significantly greater following 
LFD (81.9, SEM 1.2) than ED (78.3, SEM 1.2). There 
was good adherence for both diets.  
UNRCT: Uncontrolled and non-randomized clinical trial. NRCCT: Non-randomized controlled clinical trials. RCCT: Randomized controlled clinical trials. P/m: Period 
(months). NI: Not indicated. IBD: Inflammatory Bowel Disease. ACT: Active disease. REM: Disease in remission. SFID: Specific food intolerance diet. UCFR: Unrefined 
carbohydrate fiber rich diet. CDAI: Crohn’s Disease Activity Index. ESR: Erythrocyte sedimentation rate. F: Female. M: Male. MIAID: Mediterranean-inspired anti-inflam-
matory diet. CRP: C-reactive protein. CSS: Cross-sectional study. MED: Mediterranean diet. IBDQ: Inflammatory Bowel Disease Questionnaire. BMI: Body mass index. 
BW: Bodyweight. CC: ISO Country Codes. CD: Crohn’s Disease. EG/CG: Experimental and Control Group. FE: Serum iron. HDL: High-density lipoprotein. LDL: Low-
density lipoprotein. TG: Triglycerides. GGT: γ-glutamyl transferase. LDH: Lactate dehydrogenase. SGOT: Glutamic-oxaloacetic transaminase. SGPT: Glutamic-pyruvic 
transaminase. ALP: Alkaline phosphatase. IL-6: Serum interleukin-6. IL-10: Serum interleukin-10. HBI: Harvey–Bradshaw Index. LFD: Low FODMAP diet. SIBDQ: Short 
IBD questionnaire. IBS-QOL: IBS quality of life questionnaire. IBS-SSS: IBS severity score system. BS: Bristol Stool. CIBSC: Copenhagen IBS disease courses. FARS: FODMAP 
adherence report scale. VAS: visual analogue scales. FODMAP: Fermentable oligo-, di-, and monosaccharides and polyols. ND: Normal diet. SCCAI: Simple clinical colitis 
index. FC: Fecal calprotectin. FFQ: Food frequency questionnaire. VHI: Van Hees index. IP: Intestinal permeability. LCLM: Low calcium low microparticles diet. LCNM: 
Low calcium normal microparticles diet. NCLM: Normal calcium low microparticles diet. NCNM: Normal calcium normal microparticles diet. HEMA: Hematocrit. CA: 
Plasma calcium. ALB: Albumin. DMF-UC: Dietary modification framework for UC. IBDQ-UK: United Kingdom version of Inflammatory Bowel Disease. PMS: Partial 
Mayo score. RB: Rectal bleeding. SF: Stool frequency. PGA: Physician global assessment. MS: Mayo score. MF: Mucosa friability. EIMs: Extraintestinal manifestations. TRF: 
Transferrin. PA: Prealbumin. GISD: Gastrointestinal symptom diary. KED: Komperod Elimination diet. GFD: Gluten-free diet. GFDQ: Gluten-free diet questionnaire. CCS: 
Case-control study. TAD: Typical Australian diet. FM: Fecal microbiota. FWC: Fecal water content. FSCFA: Fecal short-chain fatty acids. PDAI: Pouchitis disease activity 
index. SUR: Surgery. CS: Cohort study. FL: Fecal lactoferrin. DH: Dietary history. IEC: Initial episode cases. RC: Relapse Cases. PBD: Plant-based diet. PBDS: Plant-based 
diet score. ED: Exclusion diet. GSRS: Gastrointestinal symptom rating scale. 7-FR: 7-day food record. SRFGS: Satisfactory relief of functional-like gastrointestinal symptoms. 
RCS: Retrospective cohort study. RCD: Refined carbohydrate diet. SVD: Semi-vegetarian diet. VD: Vegetarian diet. DQ: Dietary questionnaire. MTWAI: Modified Truelove 
and Witts activity index. SF-36: Short Form-36 health survey. SCD: Specific Carbohydrate diet. IBS: Irritable bowel syndrome. CLD: Celiac disease. WBC: White blood cells. 
PL: Platelets. IGED: Inmunoglobulin Exclusion Diet. LMD: Low microparticles diet. NMD: Normal microparticles diet. AIPD: Autoimmune protocol diet. MCDAI: Modi-
fied CDAI. MED: Mediterranean Diet. 
Table 3. Methodological quality analysis according to the CONSORT (Consolidated Standards of Reporting Trials) guide for reporting clinical trials. 
Studies 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Total Score (%) 
Berghouse et al. 1984 [39]  0 1 0 0.5 1 0.5 0 0 0 0 0.5 0.5 1 0.5 0 1 0.5 0 0 1 1 1 0 0 1 11/25 44 
Jones et al. 1985 [40] 0 1 1 1 1 0.5 0 0 0 0 0 0 1 0.5 1 1 0.5 1 0 1 1 1 0 0 1 13.5/25 54 
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Ritchie et al. 1987 [41] 0 1 0.5 1 1 0.5 0.5 1 1 1 1 0.5 0.5 1 1 1 0.5 0 0 1 1 1 0 0 1 17/25 68 
Lomer et al. 2001 [42] 1 1 0.5 0.5 1 0.5 0 0.5 0 0 1 1 1 0.5 1 1 0.5 0 0 1 1 1 0 0 0 14/25 56 
Lomer et al. 2005 [43] 0.5 1 0.5 1 1 0.5 0 1 0 0 0.5 1 0.5 1 1 1 0.5 1 0 1 1 1 0 1 1 17/25 68 
Bentz et al. 2010 [46] 0.5 1 0.5 0.5 1 0.5 0 1 0 0 1 0.5 1 0.5 0 0 0.5 0 0 1 1 1 0 0 1 12.5/25 50 
Rajendran et al. 2010 [48] 0.5 1 0.5 0.5 1 0.5 0 NA NA NA NA 0.5 NA 0.5 1 1 0.5 NA 0 1 1 1 NA NA NA 10.5/16 66 
Uzunismail et al. 2011 [49] 0.5 1 0.5 0.5 1 0.5 0 NA NA NA NA 0.5 1 0 1 0 0.5 NA 0 1 1 1 NA NA NA 10/17 59 
Marlow et al. 2013 [50] 0.5 1 1 1 1 0.5 0 NA NA NA NA 0 NA 0.5 0 1 0.5 NA 1 1 1 1 NA NA NA 11/16 69 
Kyaw et al. 2014 [52] 1 1 0.5 1 1 0.5 0 1 0 1 0.5 1 1 0.5 1 1 1 0 0 1 1 1 0 0 1 17/25 68 
Gunasekeera et al. 2016 [53] 1 1 0.5 1 1 0.5 0.5 1 1 1 1 1 1 0.5 1 1 1 1 0 1 1 1 0 0 1 20/25 80 
Halmos et al. 2016 [54] 1 1 0.5 0.5 1 0.5 0.5 1 0 1 1 1 1 1 0 1 1 0 0 1 1 1 1 1 1 19/25 76 
Komperod et al. 2017 [58] 1 1 0.5 1 1 0.5 0 NA NA NA NA 0.5 NA 1 1 1 0.5 NA 0 1 1 1 NA NA NA 11.5/16 72 
Konijeti et al. 2017 [59] 0.5 1 0.5 1 1 0.5 0 NA NA NA NA 1 NA 0.5 1 1 1 NA 1 1 1 1 NA NA NA 13/16 81 
Pedersen et al. 2017 [60] 1 1 0.5 1 1 0.5 1 0.5 0 1 0.5 1 1 0.5 1 1 1 1 0 1 1 1 0 0 1 18.5/25 74 
Jian et al. 2018 [62] 0.5 1 0.5 1 1 0.5 0 1 1 0 0.5 0.5 1 1 1 1 1 0 0 1 1 1 0 0 1 16.5/25 66 
Testa et al. 2018 [63] 0.5 1 0.5 1 1 0.5 0 NA NA NA NA 0.5 0.5 1 1 1 0.5 NA 0 1 1 1 NA NA NA 12/17 71 
Bodini et al. 2019 [64] 1 1 0.5 0.5 1 0.5 0 0.5 0 0 1 1 1 0.5 1 1 1 0 0 1 1 1 0 0 0 14.5/25 58 
Cox et al. 2020 [68] 1 1 0.5 1 1 0.5 1 1 1 1 1 1 1 0.5 1 1 1 1 1 1 1 1 1 1 1 23.5/25 94 
NA: Not applicable. 
Table 4. Methodological quality analysis according to the STROBE (Strengthening the Reporting of Observational studies in Epidemiology) guide for reporting observa-
tional studies. 
Studies 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Total 
Score 
(%) 
Heaton et al. 1979 [38] 0.5 1 1 1 1 0.5 1 1 0 0 0 0.4 0.66 1 1 0.33 0 0 0 1 1 1 11/22 50 
Croagh et al. 2007 [44] 0.5 1 1 1 0 0 1 1 0 0 0 0.4 0.66 1 1 0.33 1 1 1 1 1 1 13/22 59 
Gearry et al. 2008 [45] 0.5 1 1 1 1 1 1 1 0 0 0 0.6 0.66 1 1 0.33 1 1 1 1 1 1 15/22 68 
Chiba et al. 2010 [47] 0.5 1 1 1 1 0.5 1 1 0 0 0 0.6 0.66 1 1 0.33 1 1 1 1 1 0 13/22 59 
Herfarth et al. 2014 [51] 0.5 1 1 1 1 0 1 1 0 0 1 0.6 0.33 0.5 1 0.33 0 1 1 1 1 1 13/22 59 
Maagard et al. 2016 [55] 1 1 1 1 1 1 1 1 0 0 1 0.6 0.66 1 1 0.66 1 1 1 1 1 1 17/22 77 
Prince et al. 2016 [56] 0.5 1 1 1 1 0.5 1 1 1 0 1 0.6 0.33 1 1 0.66 1 1 1 1 1 1 16/22 73 
Suskind et al. 2016 [57] 0.5 1 1 1 1 0 1 1 0 0 1 0.2 0.33 1 1 0.33 0 1 1 1 1 1 14/22 64 
Chiba et al. 2018 [61] 0.5 1 1 1 1 0.5 1 1 0 0 1 0.6 0.66 1 1 0.33 1 1 1 1 1 1 15/22 68 
Godny et al. 2019 [65] 0.5 1 1 1 1 0.5 1 1 0 0 1 0.4 0.33 1 1 0.33 0 1 1 1 1 1 14/22 64 
Papada et al. 2019 [66] 0.5 1 1 1 1 1 1 1 0 0 1 0.6 1 0.5 1 0.33 1 1 1 1 1 1 16/22 73 
Schreiner et al. 2019 [67] 0.5 1 1 1 1 1 0 1 0 0 1 0.6 0.33 1 1 0.66 1 1 1 1 1 1 15/22 68 
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3.2. Meta-Analysis 
Only 10 clinical trials had the common quality and variables needed to be used in the 
meta-analysis. These 10 trials worked with a total of 13 groups. The final size of the sample 
was comprised of 558 observed moments for 279 individuals, all with IBD, to which a 
predefined diet had been prescribed. The common variables were the CDAI, FC, CRP, and 
ALB (Figure 3). 
For the CDAI, which is an index of disease activity used in patients with CD [69], the 
effects were positive when comparing the situation at the start and at the end of treatment 
with a predefined diet, independently if the situation with fixed effects (less probable) or 
random effects (more acceptable) was considered. However, for FC, CRP, and albumin, 
the use of a predefined diet was not significant. As for heterogeneity, the CDAI obtained 
very high values, which indicates a lack of studies, and to a lesser degree, the heterogene-
ity is shown in CRP (80%), while for albumin (52%) and the FC (2%), the heterogeneity is 











Figure 3. Forest plot for (a) Crohn’s Disease Activity Index (CDAI), (b) Fecal Calprotectin (FC), (c) 
C-Reactive Protein (CRP), and (d) Albumin (ALB). 
The influence of each study on the results of the meta-analysis is shown in Table 5, 
considering a model of random effects. For CDAI, the study from 2001 by Lomer et al. 
was the most influential; however, it is not sufficient for eliminating the high heterogene-
ity, and this corroborates the need for more studies or other covariables that could explain 
this heterogeneity. However, there are not enough studies to perform an analysis of mod-
erators or meta-regression. 
Table 5. Influence analysis in a meta-analysis using the leave-one-out method (random effect). 
 Meta−Analysis for: Effect Size (%Heterogeneity) 
ID Omitting n CDAI FC CRP ALB 
1 Lomer et al. 2001 [42] 10 −125 (93.5%)    
2 Lomer et al. 2001 [42] 10 −82 (89.5%)    
3 Lomer et al. 2005 [43] 41 −104 (96.7%)    
4 Lomer et al. 2005 [43] 42 −109 (96.7%)    
5 Chiba et al. 2010 [47] 22 −97 (96.6%)  0.1 (0.0%) 0.13 (67.4%) 
6 Chiba et al. 2010 [47] 11 −121 (96.6%)  −1.6 (80.6%) 0.14 (67.4%) 
7 Rajendran et al. 2010 [48] 29 −113 (96.7%)    
8 Marlow et al. 2013 [50] 8   −0.8 (85.0%)  
9 Halmos et al. 2016 [54] 8  −6.8 (32.3%)   
10 Konijeti et al. 2017 [59] 6  −5.1 (0.0%) −1.0 (85.2%) 0.29 (0.0%) 
11 Pedersen et al. 2017 [60] 37  −23.1 (29.5%) −1.2 (83.2%)  
12 Komperod et al. 2017 [58] 6  −34.2 (14.0%)   
13 Jian et al. 2018 [62] 49    0.07 (44.5%) 
 Pooled estimate  −107 (96.1%) −7.4 (2.3%) −0.9 (80.3%) 0.16 (51.7%) 
CDAI: Crohn´s Disease Activity Index. FC: Fecal Calprotectin. CRP: C-Reactive Protein. ALB: Al-
bumin. 
FC and ALB are not very heterogeneous, with 2.3% and 51.7%, respectively. By re-
moving the study by Konijeti et al. 2017, the heterogeneity decreased in both cases, mean-
ing it was the most discrepant study. Regarding CRP, the study by Chiba 2010 introduced 
heterogeneity at a month and a half, but at 24 months, it did not contribute. If heteroge-
neity is not eliminated, it can be deduced that more studies are needed. These results are 
reflected in the Baujat Plots (Fifure 4); the studies by Konijeti et al. 2017 (ID 5) and Chiba 
2010 (ID 10) introduce the most instability in the results of CRP and ALB. 






Figure 4. Baujat plot for (a) Crohn´s disease activity index, (b) fecal calprotectin, (c) C-reactive pro-
tein, and (d) albumin: the numbers in the plot correspond to the classification shown in Table 5. 
4. Discussion 
Our systematic review included a total of 31 studies, which compiled information 
from 5331 individuals with IBD and who had an intervention with different predefined 
diets. All the studies had a broad reach, and within the diverse effects found, CDAI, FC, 
CRP, and ALB were the most common, allowing us to conduct a meta-analysis to arrive 
at more complete conclusions. 
The main premise of these types of diets was based on the reduction of some types 
of pro-inflammatory foods and the increase of others, which are believed to promote a 
favorable intestinal microbiota [70]. In combination with the high prevalence of malnutri-
tion, the importance of diets that can modify the intestinal barrier and host immunity must 
be increased [71,72]. In fact, although we did not observe an amelioration in terms of ALB, 
CRP, and CF levels, an improvement in CDAI levels was observed through interventions 
with predefined diets, more specifically of microparticles diet, semi-vegetarian diet, and 
immunoglobulin exclusion diet, in patients with CD. 
The low FODMAP diet (LFD) reduces fermented oligosaccharides, disaccharides, 
monosaccharides, and polyols because they are poorly absorbed in the small intestine and 
are fermented by bacteria in the colon, triggering intestinal discomfort and gas in sensitive 
individuals [73–75]. This diet has been used mainly with patients with irritable bowel syn-
drome; however, it has been transferred to patients with IBD due to the similarity of func-
tional gut symptoms such as bloating, abdominal pain, wind, and diarrhea [45,75]. As for 
the results obtained in our systematic review, most of the individuals improved their 
symptoms of the disease [45,46,60,66]. This coincides with other studies, in which an im-
provement was reported due to the use of an LFD for the treatment of gastrointestinal 
symptoms [23,76]. Furthermore, according to Pedersen et al., Testa et al., Bodini et al., and 
Cox et al., the LFD reported a better quality of life, although it was measured with differ-
ent questionnaires [52,53,57,60]. Results of good adherence to this type of diet have also 
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been reported [45,53,60,65], but in terms of disease activity, the results have been contro-
versial; while for some authors no improvements were found for biomarkers or indices 
such as CRP, FC, HBI, or IBS-SSS, others did obtain improvements [45,52,53,57,60]. 
All of this, together with the concern of several authors who expressed the possibility 
that this type of diet may alter the microbiome by increasing the colonic pH, thereby al-
lowing enteropathogenic colonization and causing an increase in dysbiosis [70,77,78], in-
dicate that the use of supplementation should be considered to avoid deficiencies that 
could be caused by an LFD for long periods of time. Furthermore, it is of great importance 
that it be considered in the “induction” phase of prescription of diet modification, and if 
patients do not respond to the modification, the FODMAP restriction should be discon-
tinued [77], as it can compromise the nutritional status of the patient and, to some extent, 
can affect intestinal inflammation [78]. 
The Specific Carbohydrate Diet (SCD) is based on the hypothesis that IBD patients 
have a dysfunction of disaccharidases, which are necessary to digest and absorb disaccha-
rides and amylopectin. Therefore, high amounts of these compounds could cause an over-
growth of bacteria and intestinal lesions which can increase the intestinal permeability, 
and this is why this type of diet allows foods with carbohydrates that consist only of mon-
osaccharides and excludes disaccharides and most polysaccharides [20]. An improvement 
in the symptomatology and an increase in clinical remissions are the most important re-
sults reported by Suskind et al. [57]. 
Both SCD and LFD have the potential to contribute to vitamin D deficiency. There-
fore, their follow-up and clinical evaluation is very important due to the association of 
this deficiency with an increased risk of surgery and hospitalization [79–82]. 
The Immunoglobulin Exclusion Diet (IGED) is a dietary strategy associated with the 
identification of foods that cause a certain degree of intolerance, meaning an IgG-medi-
ated reaction that acts as a delayed-type hypersensitivity response to antigen exposure, 
all of which result in excessive protective immune responses that could lead to increased 
disease activity [83–85]. The researchers Rajendran et al., Gunasekeera et al., and Uzunis-
mail obtained improvements in the activity of the pathology through various tools. How-
ever, contradictory results were found for symptomatology, quality of life, and certain 
biochemical parameters such as CRP and ALB [40,41,49,55,68]. 
Several authors state that vegetarian dietary patterns are associated with a decrease 
in serum CRP, fibrinogen, and total leukocyte concentrations [86]. This coincides with the 
results obtained by Chiba et al., in which an improvement in the CRP, symptoms, and 
certain laboratory data could be observed [47,61]. However, it can cause an increase in 
posttraumatic stress and poorer mental health [67].  
With respect to the Mediterranean diet (MED), characterized by the consumption of 
important sources of fiber (cereals, legumes, vegetables, fruits, and nuts) and with a high 
content of chemical compounds with antioxidant properties such as flavonoids, phy-
tosterols, vitamins, terpenes, and polyphenols [79,87], we have obtained positive results 
with quality of life, HBI, FC, and cholesterol [42,59,62]. Currently, there is some contro-
versy regarding the role of this diet in IBD, as several authors indicated that a healthy diet 
pattern, which includes the MED, is associated with significant reductions in inflamma-
tion-related CRP [88], and other researchers concluded that this type of diet does not have 
significant effects on inflammatory substances [89]. 
Also, there is the gluten-free diet (GFD), which eliminates the gliadin protein located 
in wheat, barley, rye, and other grains. This diet has been traditionally used for patients 
with celiac disease and more recently in people with sensitivity to non-celiac gluten [90]. 
However, the nutrient responsible for improvement is controversial, since these cereals 
have more than one possible symptom inducer such as gluten, fructans, trypsin amylase 
inhibitors, and lectins [91–93]. The results from our systematic review are controversial. 
On the one hand, the use of this type of diet improved the symptoms of pathology; how-
ever, it could also lead to an increase in anxiety and depression, possibly due to the diffi-
culty of adherence [51,67]. These findings coincide with the results from some authors, 
Nutrients 2021, 13, 52 18 of 22 
 
who state that GFD, despite the existence of data indicating low adherence, suggests a 
potential benefit and great utility in the management of IBD [70,80]. 
Despite being the first systematic review that deals with the general effects of prede-
fined diets on adult patients with IBD, this article is not exempt from limitations. It is 
possible that the CONSORT questionnaire was not the best for evaluating the Non-ran-
domized controlled clinical trials (NRCCT) and Uncontrolled and non-randomized clini-
cal trial (UNRCT) reviewed; however, we tried to avoid this limitation by adjusting the 
items of this tool to the type of study, as no questionnaire was found that evaluated the 
Randomized controlled clinical trial (RCCT), the NRCCT, and the UNRCT [30,94]. Also, 
some studies were somewhat old, which could have reduced the score of this tool on the 
methodological quality due to the lack of standard criteria at the time the clinical trials 
were conducted. The UC and CD data were combined to perform a meta-analysis for the 
variables CDAI, FC, CRP, and ALB due to the low number of studies that separated these 
diseases to elaborate on their results and the great variability, not only of the tools used 
but also of the unit of measurement employed. However, these clinical entities have dif-
ferent clinical courses. The results derived from this work could help in clinical practice 
to help health professionals, through the creation of a guide oriented towards evaluating 
the addition of predefined diets within the set of medical therapies for an adult patient 
diagnosed with IBD. Both clinical trials and observational studies have been used within 
this systematic review, a parameter that has allowed us to have a more global view of the 
effect of intervention. 
As future lines of research, the use of other types of predefined diets should be con-
sidered, which have been observed to show positive results in such patients and for which 
little evidence is found [38,39,42,43,50,51,54,61,63,64]. 
5. Conclusions 
Predefined diets have been shown to have partial efficacy for the treatment of IBD 
and are compatible with other medical treatments. CDAI improved in patients with CD 
but with reasonable doubts due to the high heterogeneity of the data, while no differences 
were observed for ALB, FC, and CRP. LFD, IGED, MED, GFD, and vegetarian diets are 
the most studied and beneficial dietary interventions for these patients. However, there 
was a great variability in the diets and tools used to measure their interventions. In addi-
tion, the mechanisms of action of the food or nutrients responsible for the improvement 
are unknown. Thus, more studies that evaluate the influence of predefined diets on IBD 
patients are needed. 
Author Contributions: Conceptualization, J.M.C., A.G.-H., and C.A.; methodology, J.M.C., C.A., 
and P.C. formal analysis, J.M.C. and P.C.; investigation, J.M.C. and A.G.-H.; writing—original 
draft preparation, J.M.C. and P.C.; writing—review and editing, A.G.-H. and J.T.; visualization, 
J.T.; supervision, J.T. and P.C. All authors have read and agreed to the published version of the 
manuscript. 
Funding: This research received no external funding. 
Institutional Review Board: Not applicable. 
Informed Consent: Not applicable. 
Data Avoilability: Not applicable. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Chen, X.-L.; Zhong, L.; Wen, Y.; Liu, T.-W.; Li, X.-Y.; Hou, Z.-K.; Hu, Y.; Mo, C.; Liu, F.-B. Inflammatory bowel disease-specific 
health-related quality of life instruments: a systematic review of measurement properties. Health Qual. Life Outcomes 2017, 15, 
177, doi:10.1186/s12955-017-0753-2. 
2. Tárrago, C.P.; Maestu, A.P.; Miján De La Torre, A. Tratamiento nutricional en la enfermedad inflamatoria intestinal. Nutr. Hosp. 
2008, 23, 418–428. 
Nutrients 2021, 13, 52 19 of 22 
 
3. Cortés, R.L.; Fernández, B.M.; Montoro, C.H.; Hernández, P.E.; Aznarez, A.C.S.; Gutiérrez, C.R. Calidad de vida relacionada 
con la salud en pacientes con enfermedad inflamatoria intestinal. An. Sist. Sanit. Navar. 2016, 39, 123–131, doi:10.23938/S1137-
6627/2016000100014. 
4. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; 
et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of popula-
tion-based studies. Lancet (London, England) 2018, 390, 2769–2778, doi:10.1016/S0140-6736(17)32448-0. 
5. Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; 
Barkema, H.W.; et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic 
review. Gastroenterology 2012, 142, 46-54.e42, doi:10.1053/j.gastro.2011.10.001. 
6. De Boer, A.G.E.M.; Bennebroek Evertsz’, F.; Stokkers, P.C.; Bockting, C.L.; Sanderman, R.; Hommes, D.W.; Sprangers, M.A.G.; 
Frings-Dresen, M.H.W. Employment status, difficulties at work and quality of life in inflammatory bowel disease patients. Eur. 
J. Gastroenterol. Hepatol. 2016, 28, 1130–1136, doi:10.1097/MEG.0000000000000685. 
7. Lo, B.; Prosberg, M. V; Gluud, L.L.; Chan, W.; Leong, R.W.; van der List, E.; van der Have, M.; Sarter, H.; Gower-Rousseau, C.; 
Peyrin-Biroulet, L.; et al. Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel 
disease and the reliability of the inflammatory bowel disease disability index. Aliment. Pharmacol. Ther. 2018, 47, 6–15, 
doi:10.1111/apt.14373. 
8. Everhov, A.H.; Khalili, H.; Askling, J.; Myrelid, P.; Ludvigsson, J.F.; Halfvarson, J.; Nordenvall, C.; Soderling, J.; Olen, O.; Neo-
vius, M. Sick Leave and Disability Pension in Prevalent Patients With Crohn’s Disease. J. Crohns. Colitis 2018, 12, 1418–1428, 
doi:10.1093/ecco-jcc/jjy123. 
9. Casanova, M.J.; Chaparro, M.; Molina, B.; Merino, O.; Batanero, R.; Dueñas-Sadornil, C.; Robledo, P.; Garcia-Albert, A.M.; 
Gómez-Sánchez, M.B.; Calvet, X.; et al. Prevalence of malnutrition and nutritional characteristics of patients with inflammatory 
bowel disease. J. Crohn’s Colitis 2017, 11, 1430–1439, doi:10.1093/ecco-jcc/jjx102. 
10. Bergeron, F.; Bouin, M.; D’Aoust, L.; Lemoyne, M.; Presse, N. Food avoidance in patients with inflammatory bowel disease: 
What, when and who? Clin. Nutr. 2018, 37, 884–889, doi:10.1016/j.clnu.2017.03.010. 
11. Chiba, M.; Nakane, K.; Komatsu, M. Westernized Diet is the Most Ubiquitous Environmental Factor in Inflammatory Bowel 
Disease. Perm. J. 2019, 23, 18–107, doi:10.7812/TPP/18-107. 
12. Reddavide, R.; Rotolo, O.; Caruso, M.G.; Stasi, E.; Notarnicola, M.; Miraglia, C.; Nouvenne, A.; Meschi, T.; De’ Angelis, G.L.; Di 
Mario, F.; et al. The role of diet in the prevention and treatment of Inflammatory Bowel Diseases. Acta Biomed. 2018, 89, 60–75, 
doi:10.23750/abm.v89i9-S.7952. 
13. Rizzello, F.; Spisni, E.; Giovanardi, E.; Imbesi, V.; Salice, M.; Alvisi, P.; Valerii, M.C.; Gionchetti, P. Implications of the Western-
ized Diet in the Onset and Progression of IBD. Nutrients 2019, 11, doi:10.3390/nu11051033. 
14. Comeche, J.M.; Caballero, P.; Gutierrez-Hervas, A.; Garcia-Sanjuan, S.; Comino, I.; Altavilla, C.; Tuells, J. Enteral Nutrition in 
Patients with Inflammatory Bowel Disease. Systematic Review, Meta-Analysis, and Meta-Regression. Nutrients 2019, 11, 
doi:10.3390/nu11112657. 
15. Comeche, J.M.; Comino, I.; Altavilla, C.; Tuells, J.; Gutierrez-Hervas, A.; Caballero, P. Parenteral Nutrition in Patients with 
Inflammatory Bowel Disease Systematic Review, Meta-Analysis and Meta-Regression. Nutrients 2019, 11, 
doi:10.3390/nu11122865. 
16. Tomasello, G.; Mazzola, M.; Leone, A.; Sinagra, E.; Zummo, G.; Farina, F.; Damiani, P.; Cappello, F.; Geagea, A.G.; Jurjus, A.; et 
al. Nutrition, oxidative stress and intestinal dysbiosis: Influence of diet on gut microbiota in inflammatory bowel diseases. 
Biomed. Pap. 2016, 160, 461–466, doi:10.5507/bp.2016.052. 
17. Baños Madrid, R.; Salama Benarroch, H.; Morán Sánchez, S.; Gallardo Sanchez, F.; Albaladejo Meroño, A.; Mercader Martínez, 
J. Lactose malabsorption in patients with inflammatory bowel disease without activity: It would be necessary to exclude the 
lactose products in their diet to all the patients? [Malabsorción de lactosa en pacientes con enfermedad inflamatoria intestinal 
inact. An. Med. Interna 2004, 21, 212–214. 
18. Vidarsdottir, J.B.; Johannsdottir, S.E.; Thorsdottir, I.; Bjornsson, E.; Ramel, A. A cross-sectional study on nutrient intake and -
status in inflammatory bowel disease patients. Nutr. J. 2016, 15, 61, doi:10.1186/s12937-016-0178-5. 
19. Penagini, F.; Dilillo, D.; Borsani, B.; Cococcioni, L.; Galli, E.; Bedogni, G.; Zuin, G.; Zuccotti, G.V. Nutrition in Pediatric Inflam-
matory Bowel Disease: From Etiology to Treatment. A  Systematic Review. Nutrients 2016, 8, doi:10.3390/nu8060334. 
20. Aleksandrova, K.; Romero-Mosquera, B.; Hernandez, V. Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflam-
matory Bowel Diseases and Prospects for Management and Prevention. Nutrients 2017, 9, doi:10.3390/nu9090962. 
21. Gu, P.; Feagins, L.A. Dining With Inflammatory Bowel Disease: A Review of the Literature on Diet in the Pathogenesis and 
Management of IBD. Inflamm. Bowel Dis. 2020, 26, 181–191, doi:10.1093/ibd/izz268. 
22. Limketkai, B.N.; Iheozor-Ejiofor, Z.; Gjuladin-Hellon, T.; Parian, A.; Matarese, L.E.; Bracewell, K.; MacDonald, J.K.; Gordon, M.; 
Mullin, G.E. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. Cochrane Data-
base Syst. Rev. 2019, 2019, doi:10.1002/14651858.CD012839.pub2. 
23. Zhan, Y.; Zhan, Y.-A.; Dai, S.-X. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis 
and systematic review. Clin. Nutr. 2018, 37, 123–129, doi:10.1016/j.clnu.2017.05.019. 
24. Guagnozzi, D.; González-Castillo, S.; Olveira, A.; Lucendo, A.J. Nutritional treatment in inflammatory bowel disease. An up-
date. Rev Esp Enferm Dig 2012, 104, 479–488. 
25. Charlebois, A.; Rosenfeld, G.; Bressler, B. The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: 
A Systematic Review. Crit. Rev. Food Sci. Nutr. 2016, 56, 1370–1378, doi:10.1080/10408398.2012.760515. 
Nutrients 2021, 13, 52 20 of 22 
 
26. Forbes, A.; Escher, J.; Hébuterne, X.; Kłęk, S.; Krznaric, Z.; Schneider, S.; Shamir, R.; Stardelova, K.; Wierdsma, N.; Wiskin, A.E.; 
et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin. Nutr. 2017, 36, 321–347, 
doi:10.1016/j.clnu.2016.12.027. 
27. Lamb, C.A.; Kennedy, N.A.; Raine, T.; Hendy, P.A.; Smith, P.J.; Limdi, J.K.; Hayee, B.; Lomer, M.C.E.; Parkes, G.C.; Selinger, C.; 
et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. 
Gut 2019, 68, s1–s106, doi:10.1136/gutjnl-2019-318484. 
28. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, T.P. Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097, doi:10.1371/journal.pmed.1000097. 
29. Cobos-Carbó, A.; Augustovski, F. Declaración CONSORT 2010: actualización de la lista de comprobación para informar ensayos 
clínicos aleatorizados de grupos paralelos. Med. Clin. (Barc). 2011, 137, 213–215, doi:10.1016/j.medcli.2010.09.034. 
30. Campos Cañuelo, D.; Sanz-Valero, J.; Wanden-Berghe, C. Consecuencias de la nutrición parenteral domiciliaria en adultos con 
síndrome de intestino corto: revisión exploratoria. Hosp. a Domic. 2019, 3, 149, doi:10.22585/hospdomic.v3i2.60. 
31. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Peter, /; Go, C.; Tzsche E /, /; Vandenbroucke, J.P.; Von, E. The Strengthening 
the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies. 
Gac Sanit 2008, 22, 144–50. 
32. Baujat, B.; Mahé, C.; Pignon, J.P.; Hill, C. A graphical method for exploring heterogeneity in meta-analyses: Application to a 
meta-analysis of 65 trials. Stat. Med. 2002, 21, 2641–2652, doi:10.1002/sim.1221. 
33. Duval, S.; Tweedie, R. A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis. J. Am. 
Stat. Assoc. 2000, 95, 89–98, doi:10.1080/01621459.2000.10473905. 
34. Copas, J.B.; Shi, J.Q. A sensitivity analysis for publication bias in systematic reviews. Stat. Methods Med. Res. 2001, 10, 251–265, 
doi:10.1191/096228001678227776. 
35. Balduzzi, S.; Rücker, G.; Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based. Ment. Health 
2019, 22, 153–160, doi:10.1136/ebmental-2019-300117. 
36. Balduzzi S, Rücker G, Schwarzer G (2019), How to perform a meta-analysis with R: a  practical tutorial, Evidence-Based Mental 
Health; 22: 153-160.; 
37. Guido Schwarzer, James R. Carpenter and Gerta Rücker (2020). metasens: Advanced Statistical Methods to Model and Adjust 
for Bias in Meta-Analysis. R package version 0.5-0. https://CRAN.R-project.org/package=metasens; 
38. Heaton, K.W.; Thornton, J.R.; Emmett, P.M. Treatment of Crohn’s disease with an unrefined-carbohydrate, fibre-rich diet. Br. 
Med. J. 1979, 2, 764–766, doi:10.1136/bmj.2.6193.764. 
39. Berghouse, L.; Hori, S.; Hill, M.; Hudson, M.; Lennard-Jones, J.E.; Rogers, E. Comparison between the bacterial and oligosac-
charide content of ileostomy effluent in subjects taking diets rich in refined or unrefined carbohydrate. Gut 1984, 25, 1071–1077, 
doi:10.1136/gut.25.10.1071. 
40. Jones, V.A.; Dickinson, R.J.; Workman, E.; Wilson, A.J.; Freeman, A.H.; Hunter, J.O. Crohn’s disease: maintenance of remission 
by diet. Lancet (London, England) 1985, 2, 177–180, doi:10.1016/s0140-6736(85)91497-7. 
41. Ritchie, J.K.; Wadsworth, J.; Lennard-Jones, J.E.; Rogers, E. Controlled multicentre therapeutic trial of an unrefined carbohy-
drate, fibre rich diet in Crohn’s disease. Br. Med. J. (Clin. Res. Ed). 1987, 295, 517–520, doi:10.1136/bmj.295.6597.517. 
42. Lomer, M.C.; Harvey, R.S.; Evans, S.M.; Thompson, R.P.; Powell, J.J. Efficacy and tolerability of a low microparticle diet in a 
double blind, randomized, pilot study in Crohn’s disease. Eur. J. Gastroenterol. Hepatol. 2001, 13, 101–106, doi:10.1097/00042737-
200102000-00003. 
43. Lomer, M.C.E.; Grainger, S.L.; Ede, R.; Catterall, A.P.; Greenfield, S.M.; Cowan, R.E.; Vicary, F.R.; Jenkins, A.P.; Fidler, H.; Har-
vey, R.S.; et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn’s disease. 
Eur. J. Gastroenterol. Hepatol. 2005, 17, 377–384, doi:10.1097/00042737-200503000-00019. 
44. Croagh, C.; Shepherd, S.J.; Berryman, M.; Muir, J.G.; Gibson, P.R. Pilot study on the effect of reducing dietary FODMAP intake 
on bowel function in  patients without a colon. Inflamm. Bowel Dis. 2007, 13, 1522–1528, doi:10.1002/ibd.20249. 
45. Gearry, R.B.; Irving, P.M.; Barrett, J.S.; Nathan, D.M.; Shepherd, S.J.; Gibson, P.R. Reduction of dietary poorly absorbed short-
chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J. 
CROHNS COLITIS 2009, 3, 8–14, doi:10.1016/j.crohns.2008.09.004. 
46. Bentz, S.; Hausmann, M.; Piberger, H.; Kellermeier, S.; Paul, S.; Held, L.; Falk, W.; Obermeier, F.; Fried, M.; Scholmerich, J.; et 
al. Clinical relevance of IgG antibodies against food antigens in Crohn’s disease: a  double-blind cross-over diet intervention 
study. Digestion 2010, 81, 252–264, doi:10.1159/000264649. 
47. Chiba, M.; Abe, T.; Tsuda, H.; Sugawara, T.; Tsuda, S.; Tozawa, H.; Fujiwara, K.; Imai, H. Lifestyle-related disease in Crohn’s 
disease: relapse prevention by a semi-vegetarian diet. World J. Gastroenterol. 2010, 16, 2484–2495, doi:10.3748/wjg.v16.i20.2484. 
48. Rajendran, N.; Kumar, D. Food-specific IgG4-guided exclusion diets improve symptoms in Crohn’s disease: a  pilot study. 
Colorectal Dis. 2011, 13, 1009–1013, doi:10.1111/j.1463-1318.2010.02373.x. 
49. Uzunısmaıl, H.; Cengız, M.; Uzun, H.; Ozbakir, F.; Göksel, S.; Demırdağ, F.; Can, G.; Balci, H. The effects of provocation by 
foods with raised IgG antibodies and additives on the  course of Crohn’s disease: a pilot study. Turkish J. Gastroenterol.  Off. J. 
Turkish Soc.  Gastroenterol. 2012, 23, 19–27, doi:10.4318/tjg.2012.0332. 
50. Marlow, G.; Ellett, S.; Ferguson, I.R.; Zhu, S.; Karunasinghe, N.; Jesuthasan, A.C.; Han, D.Y.; Fraser, A.G.; Ferguson, L.R. Tran-
scriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn’s disease patients. Hum. Genomics 
2013, 7, 24, doi:10.1186/1479-7364-7-24. 
Nutrients 2021, 13, 52 21 of 22 
 
51. Herfarth, H.H.; Martin, C.F.; Sandler, R.S.; Kappelman, M.D.; Long, M.D. Prevalence of a gluten-free diet and improvement of 
clinical symptoms in patients with inflammatory bowel diseases. Inflamm. Bowel Dis. 2014, 20, 1194–1197, 
doi:10.1097/MIB.0000000000000077. 
52. Kyaw, M.H.; Moshkovska, T.; Mayberry, J. A prospective, randomized, controlled, exploratory study of comprehensive dietary 
advice in ulcerative colitis: impact on disease activity and quality of life. Eur. J. Gastroenterol. Hepatol. 2014, 26, 910–917, 
doi:10.1097/MEG.0000000000000127. 
53. Gunasekeera, V.; Mendall, M.A.; Chan, D.; Kumar, D. Treatment of Crohn’s Disease with an IgG4-Guided Exclusion Diet: A 
Randomized Controlled Trial. Dig. Dis. Sci. 2016, 61, 1148–1157, doi:10.1007/s10620-015-3987-z. 
54. Halmos, E.P.; Christophersen, C.T.; Bird, A.R.; Shepherd, S.J.; Muir, J.G.; Gibson, P.R. Consistent Prebiotic Effect on Gut Micro-
biota With Altered FODMAP Intake in Patients  with Crohn’s Disease: A Randomised, Controlled Cross-Over Trial of Well-
Defined Diets. Clin. Transl. Gastroenterol. 2016, 7, e164, doi:10.1038/ctg.2016.22. 
55. Maagaard, L.; Ankersen, D. V; Vegh, Z.; Burisch, J.; Jensen, L.; Pedersen, N.; Munkholm, P. Follow-up of patients with functional 
bowel symptoms treated with a low FODMAP diet. World J. Gastroenterol. 2016, 22, 4009–4019, doi:10.3748/wjg.v22.i15.4009. 
56. Prince, A.C.; Myers, C.E.; Joyce, T.; Irving, P.; Lomer, M.; Whelan, K. Fermentable Carbohydrate Restriction (Low FODMAP 
Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. In-
flamm. Bowel Dis. 2016, 22, 1129–1136, doi:10.1097/MIB.0000000000000708. 
57. Suskind, D.L.; Wahbeh, G.; Cohen, S.A.; Damman, C.J.; Klein, J.; Braly, K.; Shaffer, M.; Lee, D. Patients Perceive Clinical Benefit 
with the Specific Carbohydrate Diet for Inflammatory Bowel Disease. Dig. Dis. Sci. 2016, 61, 3255–3260, doi:10.1007/s10620-016-
4307-y. 
58. Komperød, M.J.; Sommer, C.; Mellin-Olsen, T.; Iversen, P.O.; Røseth, A.G.; Valeur, J. Persistent symptoms in patients with 
Crohn’s disease in remission: An exploratory study on the role of diet. Scand. J. Gastroenterol. 2018, 53, 573–578, 
doi:10.1080/00365521.2017.1397736. 
59. Konijeti, G.G.; Kim, N.; Lewis, J.D.; Groven, S.; Chandrasekaran, A.; Grandhe, S.; Diamant, C.; Singh, E.; Oliveira, G.; Wang, X.; 
et al. Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2017, 23, 2054–2060, 
doi:10.1097/MIB.0000000000001221. 
60. Pedersen, N.; Ankersen, D.V.; Felding, M.; Wachmann, H.; Vegh, Z.; Molzen, L.; Burisch, J.; Andersen, J.R.; Munkholm, P. Low-
FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J. Gastroenterol. 2017, 23, 
3356–3366, doi:10.3748/wjg.v23.i18.3356. 
61. Chiba, M.; Nakane, K.; Tsuji, T.; Tsuda, S.; Ishii, H.; Ohno, H.; Watanabe, K.; Ito, M.; Komatsu, M.; Yamada, K.; et al. Relapse 
Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational  Hospitalization: A Single-Group Trial. Perm. J. 2018, 
22, 17–167, doi:10.7812/TPP/17-167. 
62. Jian, L.; Anqi, H.; Gang, L.; Litian, W.; Yanyan, X.; Mengdi, W.; Tong, L. Food Exclusion Based on IgG Antibodies Alleviates 
Symptoms in Ulcerative Colitis: A Prospective Study. Inflamm. Bowel Dis. 2018, 24, 1918–1925, doi:10.1093/ibd/izy110. 
63. Testa, A.; Imperatore, N.; Rispo, A.; Rea, M.; Tortora, R.; Nardone, O.M.; Lucci, L.; Accarino, G.; Caporaso, N.; Castiglione, F. 
Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel 
Diseases and Celiac Disease. Dig. Dis. 2018, 36, 271–280, doi:10.1159/000489487. 
64. Bodini, G.; Zanella, C.; Crespi, M.; Lo Pumo, S.; Demarzo, M.G.; Savarino, E.; Savarino, V.; Giannini, E.G. A randomized, 6-wk 
trial of a low FODMAP diet in patients with inflammatory bowel disease. NUTRITION 2019, 67–68, 
doi:10.1016/j.nut.2019.06.023. 
65. Godny, L.; Reshef, L.; Pfeffer-Gik, T.; Goren, I.; Yanai, H.; Tulchinsky, H.; Gophna, U.; Dotan, I. Adherence to the Mediterranean 
diet is associated with decreased fecal calprotectin  in patients with ulcerative colitis after pouch surgery. Eur. J. Nutr. 2020, 59, 
3183–3190, doi:10.1007/s00394-019-02158-3. 
66. Papada, E.; Amerikanou, C.; Forbes, A.; Kaliora, A.C. Adherence to Mediterranean diet in Crohn’s disease. Eur. J. Nutr. 2020, 
59, 1115–1121, doi:10.1007/s00394-019-01972-z. 
67. Schreiner, P.; Yilmaz, B.; Rossel, J.-B.; Franc, Y.; Misselwitz, B.; Scharl, M.; Zeitz, J.; Frei, P.; Greuter, T.; Vavricka, S.R.; et al. 
Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being 
and a different gut microbiota, but no beneficial effects on the course of the disease. UNITED Eur. Gastroenterol. J. 2019, 7, 767–
781, doi:10.1177/2050640619841249. 
68. Cox, S.R.; Lindsay, J.O.; Fromentin, S.; Stagg, A.J.; McCarthy, N.E.; Galleron, N.; Ibraim, S.B.; Roume, H.; Levenez, F.; Pons, N.; 
et al. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent 
Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology 2020, 158, 176+, doi:10.1053/j.gastro.2019.09.024. 
69. Best, W.R.; Becktel, J.M.; Singleton, J.W.; Kern, F.J. Development of a Crohn’s disease activity index. National Cooperative 
Crohn’s Disease Study. Gastroenterology 1976, 70, 439–444. 
70. Limketkai, B.N.; Wolf, A.; Parian, A.M. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. Gastroenterol. 
Clin. North Am. 2018, 47, 155–177, doi:10.1016/j.gtc.2017.09.007. 
71. Li, S.; Ney, M.; Eslamparast, T.; Vandermeer, B.; Ismond, K.P.; Kroeker, K.; Halloran, B.; Raman, M.; Tandon, P. Systematic 
review of nutrition screening and assessment in inflammatory bowel  disease. World J. Gastroenterol. 2019, 25, 3823–3837, 
doi:10.3748/wjg.v25.i28.3823. 
72. Levine, A.; Sigall Boneh, R.; Wine, E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. 
Gut 2018, 67, 1726–1738, doi:10.1136/gutjnl-2017-315866. 
Nutrients 2021, 13, 52 22 of 22 
 
73. Ankersen, D.V.; Carlsen, K.; Marker, D.; Munkholm, P.; Burisch, J. Using eHealth strategies in delivering dietary and other 
therapies in patients with irritable bowel syndrome and inflammatory bowel disease. J. Gastroenterol. Hepatol. 2017, 32 Suppl 1, 
27–31, doi:10.1111/jgh.13691. 
74. Barrett, J.S. How to institute the low-FODMAP diet. J. Gastroenterol. Hepatol. 2017, 32 Suppl 1, 8–10, doi:10.1111/jgh.13686. 
75. Lewis, J.D.; Abreu, M.T. Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. Gastroenterology 2017, 152, 398+, 
doi:10.1053/j.gastro.2016.10.019. 
76. Marsh, A.; Eslick, E.M.; Eslick, G.D. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal 
disorders? A comprehensive systematic review and meta-analysis. Eur. J. Nutr. 2016, 55, 897–906, doi:10.1007/s00394-015-0922-
1. 
77. Barbalho, S.M.; Goulart, R. de A.; Aranao, A.L. de C.; de Oliveira, P.G.C. Inflammatory Bowel Diseases and Fermentable Oligo-
saccharides, Disaccharides, Monosaccharides, and Polyols: An Overview. J. Med. Food 2018, 21, 633–640, 
doi:10.1089/jmf.2017.0120. 
78. Gibson, P.R. Use of the low-FODMAP diet in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2017, 32 Suppl 1, 40–42, 
doi:10.1111/jgh.13695. 
79. Hou, J.K.; Lee, D.; Lewis, J. Diet and inflammatory bowel disease: review of patient-targeted recommendations. Clin. Gastroen-
terol. Hepatol. 2014, 12, 1592–1600, doi:10.1016/j.cgh.2013.09.063. 
80. Ruemmele, F.M. Role of Diet in Inflammatory Bowel Disease. Ann. Nutr. Metab. 2016, 68, 33–41, doi:10.1159/000445392. 
81. Kakodkar, S.; Mutlu, E.A. Diet as a Therapeutic Option for Adult Inflammatory Bowel Disease. Gastroenterol. Clin. North Am. 
2017, 46, 745–767, doi:10.1016/j.gtc.2017.08.016. 
82. Mouli, V.P.; Ananthakrishnan, A.N. Review article: vitamin D and inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2014, 
39, 125–136, doi:10.1111/apt.12553. 
83. Crowe, S.E.; Perdue, M.H. Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology. Gastroenterology 1992, 
103, 1075–1095, doi:10.1016/0016-5085(92)90047-3. 
84. Ortolani, C.; Pastorello, E.A. Food allergies and food intolerances. Best Pract. Res. Clin. Gastroenterol. 2006, 20, 467–483, 
doi:10.1016/j.bpg.2005.11.010. 
85. Cai, C.; Shen, J.; Zhao, D.; Qiao, Y.; Xu, A.; Jin, S.; Ran, Z.; Zheng, Q. Serological investigation of food specific immunoglobulin 
G antibodies in patients with inflammatory bowel diseases. PLoS One 2014, 9, doi:10.1371/journal.pone.0112154. 
86. Craddock, J.C.; Neale, E.P.; Peoples, G.E.; Probst, Y.C. Vegetarian-Based Dietary Patterns and their Relation with Inflammatory 
and Immune Biomarkers: A Systematic Review and Meta-Analysis. Adv. Nutr. 2019, 10, 433–451, doi:10.1093/advances/nmy103. 
87. Bifulco, M. Mediterranean diet: the missing link between gut microbiota and inflammatory  diseases. Eur. J. Clin. Nutr. 2015, 
69, 1078. 
88. Neale, E.P.; Batterham, M.J.; Tapsell, L.C. Consumption of a healthy dietary pattern results in significant reductions in C-reac-
tive protein levels in adults: a meta-analysis. Nutr. Res. 2016, 36, 391–401, doi:10.1016/j.nutres.2016.02.009. 
89. Mayr, H.L.; Tierney, A.C.; Thomas, C.J.; Ruiz-Canela, M.; Radcliffe, J.; Itsiopoulos, C. Mediterranean-type diets and inflamma-
tory markers in patients with coronary heart disease: a systematic review and meta-analysis. Nutr. Res. 2018, 50, 10–24, 
doi:10.1016/j.nutres.2017.10.014. 
90. Elli, L.; Tomba, C.; Branchi, F.; Roncoroni, L.; Lombardo, V.; Bardella, M.T.; Ferretti, F.; Conte, D.; Valiante, F.; Fini, L.; et al. 
Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from 
a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge. Nutrients 2016, 8, 84, doi:10.3390/nu8020084. 
91. Skodje, G.I.; Sarna, V.K.; Minelle, I.H.; Rolfsen, K.L.; Muir, J.G.; Gibson, P.R.; Veierød, M.B.; Henriksen, C.; Lundin, K.E.A. 
Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported  Non-Celiac Gluten Sensitivity. Gastroenterol-
ogy 2018, 154, 529-539.e2, doi:10.1053/j.gastro.2017.10.040. 
92. Skodje, G.I.; Minelle, I.H.; Rolfsen, K.L.; Iacovou, M.; Lundin, K.E.A.; Veierød, M.B.; Henriksen, C. Dietary and symptom as-
sessment in adults with self-reported non-coeliac gluten  sensitivity. Clin. Nutr. ESPEN 2019, 31, 88–94, 
doi:10.1016/j.clnesp.2019.02.012. 
93. Gibson, P.R.; Skodje, G.I.; Lundin, K.E.A. Non-coeliac gluten sensitivity. J. Gastroenterol. Hepatol. 2017, 32 Suppl 1, 86–89, 
doi:10.1111/jgh.13705. 
94. Wanden-Berghe, C.; Sanz-Valero, J. Systematic reviews in nutrition: standardized methodology. Br. J. Nutr. 2012, 107 Suppl, S3-
7, doi:10.1017/S0007114512001432. 
